Daewoong Pharmaceutical acquires cGMP approval of Nabota factory from US FDA

Published: 2018-05-18 16:26:00
Updated: 2018-05-18 16:23:45

Daewoong Pharmaceutical(CEO Seung-Ho Jeon) received an establishment inspection report(EIR) which mentioned approval for the Nabota(prabotulinumtoxin A, DWP-450) manufacturing facility from the US Food and Drug Administration(FDA). Thus, Daewoong Pharmaceutical is now prepared to acquire approval...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean





TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.